181 related articles for article (PubMed ID: 27404941)
1. Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.
Dudal S; Hinton H; Giusti AM; Bacac M; Muller M; Fauti T; Colombetti S; Heckel T; Giroud N; Klein C; Umaña P; Benincosa L; Bachl J; Singer T; Bray-French K
J Immunother; 2016 Sep; 39(7):279-89. PubMed ID: 27404941
[TBL] [Abstract][Full Text] [Related]
2. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.
Lehmann S; Perera R; Grimm HP; Sam J; Colombetti S; Fauti T; Fahrni L; Schaller T; Freimoser-Grundschober A; Zielonka J; Stoma S; Rudin M; Klein C; Umana P; Gerdes C; Bacac M
Clin Cancer Res; 2016 Sep; 22(17):4417-27. PubMed ID: 27117182
[TBL] [Abstract][Full Text] [Related]
4. First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
Schaller TH; Snyder DJ; Spasojevic I; Gedeon PC; Sanchez-Perez L; Sampson JH
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273346
[TBL] [Abstract][Full Text] [Related]
5. The PET-Tracer
Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL
Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308
[TBL] [Abstract][Full Text] [Related]
6. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
Teijeira A; Migueliz I; Garasa S; Karanikas V; Luri C; Cirella A; Olivera I; Cañamero M; Alvarez M; Ochoa MC; Rouzaut A; Rodriguez-Ruiz ME; Sanmamed MF; Klein C; Umaña P; Ponz M; Bacac M; Melero I
Theranostics; 2022; 12(3):1373-1387. PubMed ID: 35154495
[No Abstract] [Full Text] [Related]
8. The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vitro.
Hideshima T; Iwasaki A; Baba M; Yamashita Y; Shirakusa T; Okada H
Surg Today; 1996; 26(2):83-8. PubMed ID: 8919276
[TBL] [Abstract][Full Text] [Related]
9. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
10. A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes.
Kuwahara M; Kuroki M; Arakawa F; Senba T; Matsuoka Y; Hideshima T; Yamashita Y; Kanda H
Anticancer Res; 1996; 16(5A):2661-7. PubMed ID: 8917366
[TBL] [Abstract][Full Text] [Related]
11. Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy.
Kujawski M; Li L; Bhattacharya S; Wong P; Lee WH; Williams L; Li H; Chea J; Poku K; Bowles N; Vaidehi N; Yazaki P; Shively JE
BMC Cancer; 2019 Sep; 19(1):882. PubMed ID: 31488104
[TBL] [Abstract][Full Text] [Related]
12. Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.
Pan H; Liu J; Deng W; Xing J; Li Q; Wang Z
Int J Nanomedicine; 2018; 13():3189-3201. PubMed ID: 29881272
[TBL] [Abstract][Full Text] [Related]
13. Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.
Mølgaard K; Compte M; Nuñez-Prado N; Harwood SL; Sanz L; Alvarez-Vallina L
Gene Ther; 2017 Apr; 24(4):208-214. PubMed ID: 28075428
[TBL] [Abstract][Full Text] [Related]
14. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.
Peng L; Oberst MD; Huang J; Brohawn P; Morehouse C; Lekstrom K; Baeuerle PA; Wu H; Yao Y; Coats SR; Dall'Acqua W; Damschroder M; Hammond SA
PLoS One; 2012; 7(5):e36412. PubMed ID: 22574157
[TBL] [Abstract][Full Text] [Related]
15. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
Osada T; Hsu D; Hammond S; Hobeika A; Devi G; Clay TM; Lyerly HK; Morse MA
Br J Cancer; 2010 Jan; 102(1):124-33. PubMed ID: 19953093
[TBL] [Abstract][Full Text] [Related]
16. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager
Waaijer SJH; Warnders FJ; Stienen S; Friedrich M; Sternjak A; Cheung HK; van Scheltinga AGTT; Schröder CP; de Vries EGE; Lub-de Hooge MN
Clin Cancer Res; 2018 Oct; 24(20):4988-4996. PubMed ID: 29980531
[No Abstract] [Full Text] [Related]
17. CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors.
Bacac M; Klein C; Umana P
Oncoimmunology; 2016 Aug; 5(8):e1203498. PubMed ID: 27622073
[TBL] [Abstract][Full Text] [Related]
18. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
19. Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice.
Larbouret C; Robert B; Linard C; Teulon I; Gourgou S; Bibeau F; Martineau P; Santoro L; Pouget JP; Pelegrin A; Azria D
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1231-7. PubMed ID: 17967312
[TBL] [Abstract][Full Text] [Related]
20. Development of a BiTE
Frank B; Wei YL; Kim KH; Guerrero A; Lebrec H; Balazs M; Wang X
J Immunotoxicol; 2018 Dec; 15(1):119-125. PubMed ID: 30241454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
